佰仁醫療(688198.SH):2024年度淨利潤1.45億元,同比增長26.26%
格隆匯2月25日丨佰仁醫療(688198.SH)公佈2024年度業績快報,報吿期公司產品佈局日益完善,以產品競爭力為基礎加強市場拓展和覆蓋,品牌影響力持續提升,全生命週期管理理念已成行業共識,原有產品穩定增長的同時新上市產品的收入貢獻突顯,助力公司盈利能力持續增長,全年實現營業收入50,283.07萬元,同比增長35.67%。公司三大業務板塊收入均實現同比增長:心臟瓣膜置換與修復板塊同比增長64.42%,其中人工生物心臟瓣膜收入同比增長75.23%;先天性心臟病植介入治療及外科軟組織修復板塊分別同比增長15.77%、20.02%。
公司有效平衡短期投入和長期回報,各項指標良好,報吿期內實現營業利潤14,986.53萬元,同比增長24.04%;歸屬於母公司所有者的淨利潤14,546.10萬元,同比增長26.26%;基本每股收益1.06元,同比增長24.71%;剔除股份支付影響後歸屬於母公司所有者的淨利潤率32.23%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.